This cohort study examined metabolic characteristics of B cells in 32 IgG4-RD patients and 31 healthy controls. The researchers utilized UPLC-MS/MS-based metabolomics analysis to compare metabolic profiles between the patient group and healthy controls. The study aimed to identify specific metabolic signatures associated with the disease state.
Differential analysis revealed significant metabolic alterations, with 24 metabolites significantly upregulated and 124 significantly downregulated in IgG4-RD patients. Upregulation was observed in glutathione metabolism and unsaturated fatty acid biosynthesis, while various amino acid metabolism pathways were downregulated. Additionally, lipid content in B cells was significantly elevated in patients compared to controls.
Specific metabolic ratios and correlations provided further insight. The glutamate/glutamine ratio was significantly elevated in the fibrotic subgroup relative to the inflammatory subgroup. Correlation analysis showed that taurocholic acid levels correlated with serum IgG4, while dimethylglycine correlated with serum IgE levels. A panel of 14 metabolites demonstrated optimal diagnostic performance with an area under the curve (AUC) of 0.934.
Safety data, including adverse events and tolerability, were not reported. The study notes that while distinct metabolic features were revealed, these findings do not establish causation. Furthermore, the analysis was based on sorted B cells from patients and controls. Consequently, these results should be interpreted as indicative of metabolic dysregulation rather than a definitive causal mechanism.
View Original Abstract ↓
Immunoglobulin G4-related disease (IgG4-RD) is an autoimmune-mediated fibro-inflammatory disorder. Enhanced B-cell differentiation, along with its contribution to inflammatory and fibrotic pathological processes, represents a core mechanism in IgG4-RD. However, the metabolic characteristics of B cells in these patients have yet to be systematically investigated.
Targeted metabolomic analysis was performed on sorted B cells from 32 IgG4-RD patients and 31 healthy controls using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Differential metabolites between the two groups were identified using the Mann-Whitney U test and orthogonal partial least squares-discriminant analysis (OPLS-DA). Metabolic pathway enrichment analysis of differentially expressed metabolites was conducted using the MetaboAnalyst 6.0 platform. In an independent validation cohort, flow cytometry was employed to detect B-cell subpopulations, lipid content, and the expression of stearoyl-CoA desaturase 1 (SCD1).
Significant differences in metabolite profiles were observed between B cells from IgG4-RD patients and healthy controls. Compared to healthy controls, 24 metabolites were significantly upregulated and 124 metabolites were significantly downregulated in B cells from IgG4-RD patients. A panel of 14 metabolites demonstrated optimal performance in distinguishing IgG4-RD B cells from control B cells (AUC = 0.934). The upregulated metabolites were primarily enriched in pathways such as glutathione metabolism and unsaturated fatty acid biosynthesis, whereas various amino acid metabolism pathways were significantly downregulated. Lipid content was significantly elevated in B cells of IgG4-RD patients compared to healthy controls, with plasmablasts/plasma cells exhibiting the highest lipid content and fatty acid synthase expression among all B-cell subsets. The glutamate/glutamine ratio was significantly elevated in B cells of the fibrotic subgroup compared to the inflammatory subgroup of IgG4-RD. Taurocholic acid (TCA) and dimethylglycine showed correlations with serum IgG4 and IgE levels, respectively.
This study reveals distinct metabolic features of pathogenic B cells in IgG4-RD, proposing the hypothesis that metabolic dysregulation contributes to their pathogenic alterations.